• BX Home
  • Business of Biotechnology: Blog [Page 8]

Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more

BUSINESS OF BIOTECHNOLOGY

They're perfecting scientific developments that could cure the world's toughest diseases, improve food production, and even yield energy alternatives. This is the exciting world of biotechnology, where young companies fight to make innovative discoveries -- and to find new and innovative ways of funding those innovations.

Business of Biotechnology is part of Business Exchange, suggested by Arlene Weintraub. This topic contains 1,248 news and 4,696 blog items. Read updated news, blogs, and resources about Business of Biotechnology. Find user-submitted articles and reactions on Business of Biotechnology from like-minded professionals.

Blogs

Recent blog posts on this topic.

Drug Patent Expirations for Mar 22 2013more

Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.

Drug Patent Expirations for Mar 25 2013more

Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.

Drug Patent Expirations for Mar 26 2013more

Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.

Drug Patent Expirations for Apr 3 2013more

Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.

The SEC’s enforcement programme on biotechnology’s communications with...more

Copyright © thinkBiotech This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology...

Portola rolls out $115M IPO plan as more biotech outfits go publicmore

The list of biotechs going public grows longer. With public investors warming to biotech IPOs, Portola Pharmaceuticals...

Pfizer to move hundreds of workers to heart of Boston-area R&D hubmore

There's Cambridge, and then there's Kendall Square, arguably the heart of all biotech activity in the Boston area.

Biotech Chimerix shines in IPO debut as interest grows in antiviral dr...more

Chimerix sped out of the IPO gate on Thursday. The Durham, NC-based drug developer's ($CMRX) stock soared on its first...

Firm ranks top 5 biotech deals in evolving pharma R&D landscapemore

With pharma groups hunting for external innovation, an analysis shows a spike in early-stage biotech partnerships...

Top IT chief Perakslis steps down at FDAmore

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad)...

Drug Patent Expirations for Mar 22 2013more

Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.

Drug Patent Expirations for Mar 25 2013more

Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.

Drug Patent Expirations for Mar 26 2013more

Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.

Drug Patent Expirations for Apr 3 2013more

Copyright © thinkBiotech If your reader cannot render the information below, go to http://www.DrugPatentWatch.

GlaxoSmithKline measures 38-meter leap over placebo in Duchenne walkin...more

GlaxoSmithKline investigator John Kraus reviewed the long-awaited mid-stage results for its Duchenne muscular dystrophy...

Syros Pharma snags $30M funding deal to target master switches of canc...more

With licenses to breaking discoveries from labs affiliated with MIT and Harvard, Syros Pharmaceuticals has raised $30...

Bristol-Myers maps $250M manufacturing expansion to support growing R&...more

Score another big win for Greater Boston's growing biotech hub. Bristol-Myers Squibb ($BMY)--which startled the...

Omthera discounts IPO shares, prices at $8more

Omthera has priced its IPO of 8 million shares at $8 apiece, forced to offer a deep discount on the $12 to $14 range...

Acadia soars as FDA green-lights a late-stage shortcut for Parkinson's...more

Shares of Acadia Pharmaceuticals ($ACAD) shot up 44% this morning after the San Diego-based biotech announced that the...

NEA, Pfizer build a launch pad for a portfolio of orphan-drug biotechsmore

David Mott at New Enterprise Associates has spearheaded the development of an orphan drug accelerator that plans to...

VistaGen raises $36M for stem cell techmore

South San Francisco-based VistaGen Therapeutics says it's raised $36 million, selling shares to Bergamo Acquisition for...

Analysts rank the top 10 blockbuster duds in biopharmamore

Let's face it: When it comes to new drug approvals, projected blockbuster revenue is one of the sexiest aspects of the...

FDA stokes blockbuster hopes with 'breakthrough' brand for Pfizer canc...more

The FDA has endorsed Pfizer's ($PFE) high hopes for the breast cancer drug palbociclib (or PD-0332991), handing out its...

Amid cheers and jeers, GlaxoSmithKline reveals Duchenne drug hit prima...more

After keeping its mid-stage data for a closely-watched and controversial drug for Duchenne muscular dystrophy (DMD)...

Novartis ponders its option to acquire biotech Proteon in $550M dealmore

Novartis ($NVS) faces an M&A decision that has profound implications for the small biotech Proteon Therapeutics.

Top Sources: Business of Biotechnology

  • Biotech Blog
  • News
  • Health Beat
  • frontendofinnovation.blogspot.com
  • Nature Biotechnology
  • The Biotech Weblog
  • policyinnovations.org
  • Science Progress
  • LinkedIn Answers: Technology
  • World Pharma News / Published News

Most Active Users in this Topic

see all contributors in Business of Biotechnology

Featured White Papers

Post a Job

Jobs in this Topic

Process Sciences Associate Drug Product Regeneron | Rensselaer, NY
Posted: May 8
Chief Medical Officer (CMO) for Pharma/Biotech Epc Search International | North Carolina
Posted: Apr 18

Report comment contains invalid characters. ()
cancel
Search Cancel